World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-53 December 2025
ISSN: 2749-3644

NEW DRUG STRATEGIES IN CARDIOVASCULAR DISEASES

Dilfuza Ne'matovna Izzatulayeva,
Lecturer, Department of General
Medical Sciences, Namangan State University

Article history:

Received: September 28th 2025
Accepted: October 26th 2025

Abstract:

Cardiovascular diseases (CVDs) remain one of the leading causes of mortality worldwide, demanding continuous innovation in therapeutic approaches. Recent advancements in molecular biology, pharmacogenomics, and biotechnology have contributed to the development of more effective and targeted drug strategies. These include personalized medicine, gene-based therapies, novel antithrombotic agents, anti-inflammatory drugs, and compounds that improve endothelial function. Modern drug development also emphasizes reducing adverse effects and improving long-term patient outcomes. This paper highlights emerging pharmacological strategies aimed at preventing, managing, and treating cardiovascular diseases through innovative, evidence-based approaches.

Keywords: Cardiovascular diseases; new drug strategies; personalized medicine; gene therapy; antithrombotic agents; endothelial function; pharmacotherapy; cardiovascular pharmacology.

Cardiovascular diseases (CVDs) encompass a wide range of disorders affecting the heart and blood vessels, including coronary artery disease, hypertension, arrhythmias, and heart failure. Despite advancements in diagnostics and treatment, CVDs continue to pose significant public health challenges due to their high prevalence and mortality rates. Traditional pharmacological treatments—such as beta-blockers, ACE inhibitors, statins, and antiplatelet medications—have played a foundational role in clinical practice. However, limitations in efficacy, side effects, and variability in patient response highlight the need for more advanced therapeutic strategies.In recent years, scientific progress in genomics, molecular mechanisms of disease, and targeted drug delivery has opened new horizons for cardiovascular pharmacotherapy. Novel drug strategies now prioritize individualized treatment plans, improved safety profiles, and therapies that address the underlying molecular pathways of disease progression. These innovations include gene editing technologies, small-molecule inhibitors, monoclonal antibodies, RNA-based treatments, and regenerative medicine approaches. By integrating modern scientific discoveries with clinical practice, new drug strategies aim to reduce the global burden of cardiovascular diseases and enhance patient quality of life.

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, prompting continuous efforts to develop innovative and more effective therapeutic strategies. Traditional pharmacological treatments—such as beta-blockers, ACE inhibitors, statins, and anticoagulants—have significantly reduced CVD-related complications. However, increasing rates of drug resistance, adverse effects, and complex comorbidities have strengthened the demand for novel drug approaches that target the underlying molecular mechanisms of cardiac dysfunction.One of the most promising directions involves gene-based therapies, which aim to correct or modify genetic abnormalities contributing to myocardial degeneration, arrhythmias, and vascular disorders. Techniques such as CRISPR/Cas9 gene editing, RNA interference, and viral vector–mediated gene delivery offer new opportunities to regulate the expression of proteins responsible for cardiac remodeling, endothelial dysfunction, and inflammation. Although these methods are still under clinical evaluation, early research indicates their potential to provide long-term therapeutic benefits.Another emerging strategy includes targeted drug delivery systems designed to enhance drug bioavailability and reduce systemic toxicity. Nanoparticle-based carriers, liposomes, and polymeric delivery platforms can transport therapeutic molecules directly to damaged heart tissues or unstable arterial plaques. This approach improves drug absorption, ensures controlled release, and minimizes side effects, particularly in patients with chronic heart failure or ischemic conditions.

In addition, anti-inflammatory and immunomodulatory therapies have gained importance due to the recognized role of chronic inflammation in atherosclerosis and myocardial injury. New agents that inhibit cytokines such as IL-1β, TNF-α, and IL-6 are being investigated for their ability to slow disease progression and prevent recurrent cardiovascular events. Similarly, monoclonal antibodies and small-molecule inhibitors targeting

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-53 December 2025
ISSN: 2749-3644

inflammatory pathways have demonstrated encouraging results in clinical trials.

Recent developments also include metabolic-based medications that optimize cardiac energy production. Drugs such as SGLT2 inhibitors, originally developed for diabetes management, have shown cardioprotective effects by improving myocardial metabolism, reducing oxidative stress, and lowering the risk of heart failure–related hospitalizations. This has opened a new field of research focused on metabolic reprogramming as a therapeutic target.Finally, regenerative medicine and stem cell therapies are being explored to repair damaged myocardium and restore functional heart tissue. Mesenchymal stem cells, induced pluripotent stem cells, and cardiac progenitor cells have demonstrated their ability to promote tissue regeneration, enhance vascularization, and modulate immune responses. Although challenges remain regarding safety, differentiation control, and long-term efficacy, regenerative approaches hold considerable promise for the future of cardiovascular treatment.Modern pharmacotherapy for cardiovascular diseases is shifting toward personalized, mechanism-based, and minimally invasive strategies. As scientific understanding of molecular pathways deepens, new drug innovations are expected to improve treatment outcomes and significantly reduce the global burden of cardiovascular disorders.

Recent advances in molecular biology have allowed the development of RNA-based therapeutics, which represent another important direction in cardiovascular drug innovation. Small interfering RNA (siRNA) and microRNA (miRNA) modulators are being tested for the treatment of dyslipidemia, myocardial remodeling, and arrhythmias. Inclisiran, an siRNA targeting PCSK9, has shown long-lasting LDL-lowering effects with only two injections per year, demonstrating the potential of gene-silencing mechanisms for long-term cardiovascular risk reduction. Similar RNA-targeting strategies are being developed to regulate inflammation-related genes, cardiac hypertrophy pathways, and fibrosis-inducing molecular signals.Another promising class includes anti-inflammatory agents, as chronic inflammation is now recognized as a central contributor to atherosclerosis and heart failure. Clinical trials of interleukin-1β inhibitors and colchicine have demonstrated meaningful reductions in cardiovascular events, highlighting the role of targeted immunomodulation. Ongoing research aims to refine these therapies to enhance safety, lower systemic side effects, and personalize anti-inflammatory treatment based on individual biomarker profiles.

Regenerative medicine is also emerging as an innovative therapeutic strategy. Stem-cell–based therapies, including mesenchymal stem cells, induced pluripotent stem cells, and cardiac progenitor cells, seek to restore damaged myocardial tissue and improve cardiac function after myocardial infarction. Although challenges remain—such as cell survival, targeted delivery, and long-term integration—biomaterial scaffolds and engineered tissue constructs are showing promising preclinical outcomes. Combination therapy approaches that unite regenerative cells with growth factors or gene editing technologies, such as CRISPR/Cas9, may provide more durable and effective myocardial repair.

Furthermore, precision medicine and digital therapeutics are reshaping cardiovascular disease management. Pharmacogenomic testing allows clinicians to tailor antiplatelet, anticoagulant, and antihypertensive therapies to a patient's genetic profile, reducing adverse drug reactions and improving treatment efficacy. Artificial intelligence–assisted tools can predict cardiovascular risk, optimize dosing strategies, and support early detection of treatment failure, thereby improving outcomes through timely intervention.The exploration of gut microbiota–modulating therapies represents a novel frontier. Metabolites such as trimethylamine N-oxide (TMAO) have been linked to atherosclerosis progression. Therapeutic strategies aimed at reducing TMAO production, including enzyme inhibitors, probiotics, and dietary interventions, are currently under investigation. These therapies could offer a non-invasive and holistic approach to cardiovascular risk reduction through metabolic reprogramming.Contemporary drug strategies for cardiovascular diseases are moving toward mechanisms that combine molecular precision, long-term efficacy, and personalized approaches. By integrating genomic insights, regenerative techniques, targeted immunotherapy, and advanced digital tools, future therapies are expected to achieve improved patient outcomes and significantly lower global cardiovascular morbidity and mortality.

CONCLUSION.

Advancements in cardiovascular pharmacotherapy are rapidly transforming traditional treatment paradigms. Novel drug strategies—including molecular-targeted therapies, gene-based interventions, nanotechnology-supported delivery systems, and personalized medicine—offer more effective and safer solutions for preventing and treating cardiovascular diseases. These innovations aim to reduce global disease burden, enhance long-term outcomes, and address unmet clinical needs. Continued research,

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-53 December 2025
ISSN: 2749-3644

clinical trials, and interdisciplinary collaboration will be essential for translating these emerging strategies into routine medical practice.

REFERENCES

1. Cardiovascular Diseases Kill 10000 People in the WHO European Region Every Day, with Men Dying More Frequently than Women. 2024. Available online: https://www.who.int/azerbaijan/news/item/15-05-2024-cardiovascular-diseases-kill-10-000-people-in-the-who-european-region-every-day--with-men-dying-more-frequently-than-women (accessed on 28 April 2025).
2. ?GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023, 402, 203–234. [Google Scholar] [CrossRef] [PubMed]
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017, 390, 2627–2642. [Google Scholar] [CrossRef] [PubMed]
4. Lawrence, J.M.; Divers, J.; Isom, S.; Saydah, S.; Imperatore, G.; Pihoker, C.; Marcovina, S.M.; Mayer-Davis, E.J.; Hamman, R.F.; Dolan, L.; et al. Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017. JAMA 2021, 326, 717–727. [Google Scholar] [CrossRef] [PubMed]
5. Rao, V.N.; Zhao, D.; Allison, M.A.; Guallar, E.; Sharma, K.; Criqui, M.H.; Cushman, M.; Blumenthal, R.S.; Michos, E.D. Adiposity and Incident Heart Failure and its Subtypes: MESA (Multi-Ethnic Study of Atherosclerosis). JACC Heart Fail. 2018, 6, 999–1007. [Google Scholar] [CrossRef]
6. Mazin, I.; Chernomordik, F.; Fefer, P.; Matetzky, S.; Beigel, R. The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. J. Clin. Med. 2022, 11, 1904. [Google Scholar] [CrossRef]